Business Wire

Milken Institute and Motsepe Foundation Launch Technology Prize Program to Propel Innovation and Entrepreneurship in Africa

28.4.2021 12:01:00 EEST | Business Wire | Press release

Share

The Milken Institute and the Motsepe Foundation today launched the Milken-Motsepe Innovation Prize program, a multi-year initiative to focus global innovators and entrepreneurs on developing technological solutions that accelerate progress towards implementing the United Nations’ Sustainable Development Goals (SDGs), with a spotlight on the African continent. This program will include multiple technology prize competitions in the areas of agriculture, energy, education, and health.

“Fourth Industrial Revolution (4IR) technologies have the power to solve complicated socio-economic and human problems. In the hands of entrepreneurs, these technologies can turn Africa into a global economic powerhouse and transform the world,” said Dr. Patrice Motsepe, Founder and Chairman of the Motsepe Foundation. “Precious and I are thrilled to partner with Mike Milken and the Milken Institute to launch this prize that encourages African and global entrepreneurs to innovate and use 4IR technologies to address some of Africa and the world’s most pressing challenges and improve the living conditions and standards of living of people globally.”

Registration is now open for the first of these free-to-enter prizes. The Milken-Motsepe Prize in AgriTech is a $2 million (USD) global competition for innovative solutions to increase economic value to farmers, from seed to sale.

“My good friends Patrice and Precious Motsepe have long been valued partners of the Milken Institute, especially in addressing global health issues,” said Milken Institute Chairman Mike Milken. “The Motsepe Foundation’s leadership has been highly effective in Africa and inspiring to people around the world. I’m delighted that we will again join forces to encourage long-term technological innovation and enhance the human capital of farmers so they can play a greater role in sustaining a more-dynamic regional economy.”

Dr. Precious Moloi-Motsepe, Co-founder and CEO of the Motsepe Foundation, added: “This prize competition will tap into global entrepreneurial and technological potential, including among women and the growing youth population across the African continent and worldwide. We’re confident that the competition will attract a diverse group of participants across the world who want to engage with a broad network of resources to action their innovative ideas.”

The Milken-Motsepe Prize in AgriTech was developed through rigorous and inclusive consultations with more than 50 experts from a variety of disciplines, representing academia, industry and government, to define the competition guidelines and evaluation metrics. Field testing will take place in Africa and solutions should have the potential to be applied globally.

“Prize competitions encourage innovation, diversify the talent pool, and inspire new voices from budding entrepreneurs to seasoned engineers,” said Dr. Emily Musil Church, senior director in the Milken Institute’s Center for Global Market Development. “We are pleased to introduce this approach to advancing the SDGs that will harness the power of technology to solve global challenges and create true systems of change.”

How to Enter

Teams have until December 8, 2021 to register and submit designs and business models. An independent panel of expert judges will select up to 25 teams to each receive $10,000 to develop small-scale prototypes over the ensuing six months. In the final round, teams will demonstrate their entries in field tests which will be evaluated by their ability to:

  • Increase net economic value to the farmer
  • Increase productivity at harvest and/or decrease post-harvest loss
  • Reduce costs for farmers
  • Provide a viable and sustainable business model
  • Be implemented by small and medium-sized farms
  • Develop or integrate innovative technologies

The judges will award a $1 million Grand Prize, with additional prize money distributed among Second and Third Place winners, a prize for the most creative use of Fourth Industrial Revolution technologies and a People’s Choice Prize.

Registration is free, and in addition to the prize money, teams will benefit from access to networking, training, and other resources. To register for the prize, or to learn more, visit www.milkenmotsepeprize.org.

About the Milken Institute

The Milken Institute is a nonprofit, nonpartisan think tank that helps people build meaningful lives, in which they can experience health and well-being, pursue effective education and gainful employment, and access the resources required to create ever-expanding opportunities for themselves and their broader communities. For more information, visit www.milkeninstitute.org

About the Motsepe Foundation

The Motsepe Foundation was founded in 1999 by Dr Patrice Motsepe and his wife, Dr Precious Moloi-Motsepe. The goal of the Motsepe Foundation is to contribute towards eradicating poverty and to sustainably improve the living conditions and standards of living of poor, unemployed and marginalised people in South Africa, Africa and the world. In January 2013 Dr Patrice Motsepe and Dr Precious Moloi-Motsepe joined the Giving Pledge which was started by Warren Buffett and Bill and Melinda Gates. The Motsepes committed to give half of their wealth to the poor and for philanthropic purposes during their lifetime and beyond.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Milken Institute:
Enxhi Myslymi, emyslymi@milkeninstitute.org, +1 (203) 721 4840

Motsepe Foundation:
Jongisa Magagula, jongisa.magagula@arm.co.za, +27 82 562 5288
Jade Kunstler, Jade.kunstler@arm.co.za, +27 76 950 2707

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye